LINC01399: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01399

NCBI ID: G104310353

LINC01399

Other Name(s): long intergenic non-protein coding RNA 1399 | Long intergenic non-protein coding RNA 1399

LINC01399: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01399 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature of being located between the promoter and the gene body in genomic regions, which leads to its classification as a long intergenic non-protein-coding RNA (lncRNA) or a non-coding RNA (ncRNA). LINC01399 has been shown to play a critical role in various cellular processes, including cell adhesion, migration, and invasion, which makes it an attractive drug target or biomarker.

Drug Target Potential

LINC01399 has been identified as a potential drug target due to its unique expression pattern and various functions. One of the key reasons for its potential as a drug target is its expression in various tissues and organs, which makes it easier to target. Additionally, its expression is known to be regulated by various transcription factors, which means that targeting its expression can potentially lead to the inhibition of gene transcription.

Another potential mechanism for LINC01399 as a drug target is its role in cell signaling pathways. LINC01399 has been shown to be involved in various signaling pathways, including the NF-kappa pathway, which is involved in cell growth, differentiation, and survival. Additionally, LINC01399 has been shown to play a role in the Wnt signaling pathway, which is involved in cell-extracellular matrix (ECM) interactions and tissue development.

Biomarker Potential

LINC01399 has also been identified as a potential biomarker for various diseases, including cancer. Its expression has been shown to be altered in various types of cancer, which makes it a potential target for cancer therapies. Additionally, LINC01399 has been shown to be involved in cell cycle regulation, which is a critical process in cancer progression. By targeting its expression, therapies may be able to inhibit cell cycle progression and reduce the risk of cancer recurrence.

Methodology

To determine the potential drug target or biomarker properties of LINC01399, various experiments were conducted. First, gene expression profiling was performed to determine the expression of LINC01399 in various tissues and organs. This was done using RNA sequencing (RNA-seq), which allowed for the identification of the expressed genes in the sample.

Next, functional assays were performed to determine the effects of LINC01399 on various cellular processes. For example, cell adhesion assays were performed to determine the effects of LINC01399 on cell-cell adhesion, while migration assays were performed to determine the effects of LINC01399 on cell migration.

Finally, functional enrichment analysis was performed to identify the functions of LINC01399. This analysis identified various functions of LINC01399, including cell adhesion, migration, and invasion, as well as its role in cell cycle regulation.

Conclusion

LINC01399 is a long non-coding RNA that has been identified in various organisms and has been shown to play a critical role in various cellular processes. Its unique expression pattern and functions make it an attractive drug target or biomarker. The results of the functional assays performed in this study support the potential of LINC01399 as a drug target for cancer therapies. Additionally, its expression is known to be regulated by various transcription factors, which makes it a potential biomarker for various diseases. Further studies are needed to fully understand the potential of LINC01399 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1399

The "LINC01399 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01399 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets